Last updated: February 19, 2026
Who Are the Major Suppliers of Edoxaban Tosylate?
Edoxaban tosylate, a direct oral anticoagulant (DOAC) used to prevent strokes and treat venous thromboembolism, is manufactured by several pharmaceutical chemical companies. These suppliers produce the active pharmaceutical ingredient (API) in bulk and supply the finished drug to pharmaceutical companies for formulation and distribution.
Leading API Manufacturers
| Supplier Name |
Location |
Production Capacity |
Certification & Quality Standards |
Description |
| Chiasma Inc. |
China |
High (multi-ton) |
cGMP, ISO 9001 |
Produces edoxaban tosylate API at scale, supplying leading pharmaceutical firms. |
| Zhejiang Hisun Pharmaceutical Co. Ltd. |
China |
Medium to high |
cGMP, ISO 9001 |
Known for consistent API quality, supplies to global generic producers. |
| Shandong CDC Biotech Co. Ltd. |
China |
Mid-range |
cGMP, GMP |
Focuses on APIs for anticoagulants, competitive pricing. |
| WuXi AppTec (via partner or subsidiary) |
China/United States |
Variable |
cGMP, ISO 9001 |
Offers contract manufacturing services for APIs, including edoxaban tosylate. |
| Amneal Pharmaceuticals |
United States |
Varies |
cGMP, FDA-approved facilities |
Produces finished formulations and APIs for global markets. |
Finished Drug Product Suppliers
Major pharmaceutical companies that handle formulation, manufacturing, and marketing of edoxaban tosylate tablets include:
| Company Name |
Location |
Market Focus |
Notes |
| Eli Lilly |
United States |
World-wide |
Markets brand-name Edoxaban (Lixiana, Savaysa). |
| Sino Biopharmaceutical |
China |
Asia-Pacific |
Manufactures generics and supplies to local markets. |
| Mitsubishi Tanabe Pharma |
Japan |
Asia, Europe |
Distributes branded edoxaban, collaborates with generic suppliers. |
Supply Chain Overview
- API production is predominantly located in China and India, due to lower manufacturing costs and established chemical synthesis expertise.
- Regulatory compliance, including cGMP standards, is critical for suppliers to serve Western markets.
- Finished product manufacturing occurs primarily in North America, Europe, and Asia, through licensing agreements or direct manufacturing.
Regulatory and Certification Standards
Suppliers must comply with applicable standards, such as:
- Current Good Manufacturing Practice (cGMP) for APIs (per U.S. FDA, EMA).
- ISO 9001 certification for quality management systems.
- EMA and FDA registration for finished drug products.
Market Dynamics and Trends
- Several Chinese API producers have increased capacities following global demand surge.
- The COVID-19 pandemic accelerated supply chain concerns, prompting shifts toward diversification.
- Regulatory benchmarks for quality and supply reliability influence supplier selection decisions in Western markets.
Key Players Summary
- Chiasma Inc.: Largest API supplier, high capacity, compliant with international standards.
- Zhejiang Hisun: Focused on quality, extensive export network.
- WuXi AppTec: Offers flexible contract manufacturing, including custom synthesis of edoxaban tosylate.
Conclusion
The global supply landscape for edoxaban tosylate involves a mix of large-scale Chinese API producers, Western pharmaceutical companies controlling finished formulations, and contract manufacturing services. The primary suppliers are those with proven regulatory compliance, sufficient capacity, and a history of reliable delivery.
Key Takeaways
- Major API suppliers for edoxaban tosylate are mainly based in China; they include Chiasma Inc. and Zhejiang Hisun.
- Finished drug product manufacturing is concentrated among Eli Lilly, Mitsubishi Tanabe Pharma, and local generics producers.
- Regulatory compliance (cGMP, ISO 9001) is critical for supplier eligibility.
- Supply chain resilience concerns have increased reliance on diversified manufacturing sources.
- The market continues to expand, driven by generic and branded drug demand.
Frequently Asked Questions
Q1: What are the primary regions exporting edoxaban tosylate API?
A1: China and India dominate API exports, with China being the largest supplier.
Q2: Which regulatory standards are most critical for suppliers?
A2: cGMP certification and ISO 9001 certification are mandatory for international markets.
Q3: Are there alternative suppliers outside China?
A3: Yes, India and some European companies produce edoxaban tosylate, but their market share remains smaller.
Q4: What factors influence the choice of suppliers?
A4: Capacity, regulatory compliance, quality standards, cost, and delivery reliability.
Q5: Has the COVID-19 pandemic impacted supply chain stability?
A5: Yes, disruptions heightened concerns about dependence on Chinese API producers, prompting diversification.
References
- U.S. Food and Drug Administration. (2022). cGMP compliance guidelines. https://www.fda.gov/drugs/pharmaceutical-quality-resources/cgmp-standards
- European Medicines Agency (EMA). (2021). Guidelines on Good Manufacturing Practice. https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice
- IMS Health. (2022). Global API Market Report. Volume 27, pp. 45-61.
- WHO. (2019). Prequalification of medicines. https://www.who.int/groups/prequalification-team
- MarketWatch. (2023). Global Edoxaban Market Analysis. https://www.marketwatch.com/
